Alvogen and Pfenex' PF708 teriparatide biosimilar is now under formal review by the European Medicines Agency after the regulator accepted the firm’s marketing authorization application (MAA) through Europe’s centralized procedure.
Alvogen And Pfenex Have Teriparatide Filing Accepted By EMA
The EMA has formally accepted for filing Alvogen and Pfenex’ centralized marketing authorization application for a biosimilar rival to Lilly’s Forsteo teriparatide blockbuster.
More from Biosimilars
More from Products
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.